Loading cancer entity…
Loading cancer entity…
Variants & evidence
6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCNE1 Amplification1 | ||||||||
| Fadraciclib + TaselisibCombination | Endometrial Serous Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10181Analysis of 5 uterine serous carcinoma (USC) primary cell lines in vitro indicated enhanced sensitivity to CDK2/9 inhibitor CYC065 in cell lines overexpressing cyclin E1 (CCNE1) in comparison to low C… (full text at CIViC) PMID 27351214 · Cocco et al., 2016 · Open in CIViC | civic |
| ERBB2 Amplification3 | ||||||||
| (prognostic) | Endometrial Serous Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1096In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient… (full text at CIViC) PMID 15746676 · Santin et al., 2005 · Open in CIViC | civic |
| Trastuzumab | Endometrial Serous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1097HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer. HER2 overexpression in USPC is… (full text at CIViC) PMID 18555254 · Santin et al., 2008 · Open in CIViC | civic |
| Carboplatin/Paclitaxel Regimen + TrastuzumabCombination | Endometrial Serous Adenocarcinoma | Predictive | ||||||
| ERBB2 Overexpression1 | ||||||||
| Carboplatin + Paclitaxel + TrastuzumabCombination | Endometrial Serous Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7386In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC | civic |
| POLE R1233*1 | ||||||||
| (oncogenic) | Endometrial AdenocarcinomaCURATED_BROADER | Oncogenic | C | Does Not Support Oncogenicity | 2 | submitted | EID12525Studies submitted to cBioPortal (including 164 TCGA studies) were evaluated for POLE variants co-occurring with features of POLE-mutated tumors and co-occurring B2M variants. A single individual with … (full text at CIViC) PMID 29320758 · Voutsadakis, 2018 · Open in CIViC | civic |
Data updated 10 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B |
| Supports Sensitivity Response |
| 4 |
| submitted |
EID11322In this randomized, phase II trial, 61 patients with primary stage III or IV or recurrent HER2/neu-positive uterine serous carcinoma. Participants were randomly assigned to receive carboplatin-paclita… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC |
| civic |